EP Patent

EP1684793B1 — Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant

Assigned to Novo Nordisk AS · Expires 2011-09-21 · 15y expired

What this patent protects

Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.

USPTO Abstract

Pharmaceutical composition for parenteral administration comprising a meal related insulin peptide and an insulinotropic peptide.

Drugs covered by this patent

Patent Metadata

Patent number
EP1684793B1
Jurisdiction
EP
Classification
—
Expires
2011-09-21
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.